Multiple Myeloma Research Foundation (MMRF) Welcomes Nodality President and CEO David Parkinson, M.D. to Board of Directors

Al Roker and James T. Brown Join Honorary Board of Directors

Norwalk, CT — September 8, 2010

The Multiple Myeloma Research Foundation (MMRF) today announced that David Parkinson, M.D., President and CEO of Nodality, Inc. has joined its Board of Directors. Nodality is a San Francisco-based biotechnology company developing next-generation diagnostics in oncology and auto-immune diseases to enable more personalized treatment approaches.

“Dr. Parkinson brings a wealth of expertise in drug discovery and development to the Foundation, and we are honored to have him aboard,” said Kathy Giusti, Founder and CEO of the MMRF. “His impressive background in oncology, and commitment to orphan cancers, will enhance our leadership as we continue to accelerate the development of promising next-generation treatments for myeloma patients, particularly in the field of personalized medicine.”

Prior to leading Nodality, Dr. Parkinson held senior-level positions at Biogen Idec, Amgen, Novartis and the National Cancer Institute. Dr. Parkinson was instrumental in bringing Novartis’ Gleevec® (imatinib mesylate) to market, completely transforming the treatment of Chronic myelogenous leukemia (CML). Dr. Parkinson also previously served as the Chairman of the U.S. Food and Drug Administration (FDA) Biologics Advisory Committee and was a recipient of the FDA's Cody Medal.

In addition to increasing the strength of leadership represented on its Board of Directors, the MMRF also announced that iconic television personalities Al Roker and James T. Brown have joined its Honorary Board of Directors. Roker and Brown will bring tremendous energy to this elite group of MMRF supporters.

“We are delighted to welcome both Al Roker and James T. Brown to the MMRF’s Honorary Board,” said Giusti. “We are looking forward to their continued involvement in support of our mission.”

Roker is a best-selling author, co-host of the Today Show on NBC, and a seven-time Emmy Award winner. Roker, whose grandmother was a multiple myeloma patient, recently served as emcee at the MMRF’s Eighth Annual Laugh for Life: New York, a premier comedy event held this past May.

Brown, three-time Emmy Award winner, Sports Illustrated’s “Best Studio Host of the Decade” and author, hosts both The NFL Today on CBS and Inside the NFL on Showtime. Brown delivered a moving address as Keynote Speaker at the MMRF’s Ninth Annual Chicago Awards Dinner this past April.


About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $140 million since its inception to fund nearly 120 laboratories worldwide, including 50 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 26 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.

Media Contact:
Terri Clevenger
Continuum Health Communications
Tel: 203-227-0209

Debra Venech
Marketing Communications Manager
Multiple Myeloma Research Foundation
Tel: 203-652-0232